Chinese clinical-stage biopharmaceutical firm Reistone Biopharma has secured nearly $100 million in a Series A round of financing to speed up the development of novel medicines for the treatment of immune and inflammation-related diseases.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
